Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
THUNDER trial in high-risk prostate cancer
2022-501551-90-00Phase 3Authorised
- Sponsor
- Ziekenhuis Aan De Stroom
- Start
- Sep 2023
- Modality
- Small Molecules, Peptides, Classical Binding Small Molecules → Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised trial of darolutamide, docetaxel, goserelin, leuprolide, triptorelin and 2 more in prostate cancer (PCa) (5 arms), sponsored by Ziekenhuis Aan De Stroom. Primary endpoints: PSMA PET metastatic progression-free survival and Health-related quality of life by EPIC. Planned start Sep 2023; status: authorised.
02
Drugs
darolutamidedocetaxelgoserelinleuprolidetriptorelin
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2022-501551-90-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-501551-90-00.